First Reliance Bancshares Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of First Reliance Bancshares, Inc.

Kahn Swick & Foti, LLC is investigating the proposed sale of First Reliance Bancshares (OTC: FSRL) to Colony Bankcorp (NYSE: CBAN), where FSRL shareholders would receive $19.75 cash or 0.94 shares of CBAN stock per FSRL share. The inquiry adds overhang around the transaction terms and potential shareholder outcomes.

Analysis

This reads more like a process-risk event than a fundamental re-rating. In small-bank M&A, the first order impact is usually on the target’s deal spread, while the second order effect is on the acquirer’s ability to use stock as cheap currency in future deals; even a nuisance challenge can make boards demand a wider certainty premium. The immediate market response should be modest unless the complaint surfaces a real process defect, because these investigations often monetize delay rather than conviction.

The bigger mechanism is election/consideration risk: if the mix allows cash or stock, the stock leg makes the transaction sensitive to CBAN’s own share performance and can create hidden dilution if elections skew toward stock. Over 1-3 months, watch whether the spread stays anchored near the implied exchange value or starts to widen on low volume; a widening spread would signal the market is pricing either proration complexity or closing delay, not necessarily deal failure.

Contrarian take: the consensus tends to overread these law-firm probes as deal-threatening when, in most community-bank combinations, they are largely settlement leverage. The more meaningful falsifier is not the lawsuit headline but a change in proxy disclosures, a revised fairness opinion, or evidence that the board process was narrow and non-competitive. Absent that, the event likely matters only to merger-arb desks, not to long-only holders.

Key Decisions for Investors

• Do not chase either ticker on the investigation headline; treat this as a low-conviction spread item unless the discount to deal value widens meaningfully after the proxy filing.
• If already long FSRL in merger arb, reduce beta by hedging with CBAN until the definitive proxy clarifies cash-vs-stock election mechanics and any proration risk.
• Set an event alert for the merger proxy / shareholder vote. If no clean disclosure on process and consideration mix arrives within 30-45 days, assume delay risk is rising and reassess the arb.
• Use CBAN as the cleaner expression of negative optionality if the market starts pricing legal delay into the buyer’s stock; otherwise stay flat rather than forcing a trade in an illiquid OTC target.